Hospital
Southwest General Hospital LP
Southwest General Hospital LP was paid $5.84M by Medicaid between Aug 2019 and Apr 2023, across 74 billing codes. Its largest line is 99285, emergency room visit (most serious) — 51% of everything it billed.
33Billing provider infoSOUTHWEST GENERAL HOSPITAL LP
SAN ANTONIO, TX 78224
SAN ANTONIO, TX 78224
33aNPI1912906298assigned 07/19/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.84M
24GClaims79,821
24DCodes billed74
24AFirst – last monthAug 2019 – Apr 2023
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#33 of 109
Median peer was paid$1.15M
This provider vs. median5.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOYLE, JOHN controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 14 | $3K | |
| 2020 | 3,412 | $186K | |
| 2021 | 32,312 | $2.20M | |
| 2022 | 37,230 | $2.77M | |
| 2023 | 6,853 | $680K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 51% | 5,175 | 4,682 | $2.96M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 32% | 7,383 | 6,833 | $1.88M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.0% | 4,924 | 4,707 | $351K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 2,390 | 2,165 | $128K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 4,632 | 4,176 | $78K |
| 80053 | Comprehensive metabolic panel | <1% | 6,156 | 5,642 | $52K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 895 | 837 | $46K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,990 | 6,314 | $43K |
| 80050 | General health panel | <1% | 877 | 809 | $38K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,870 | 1,753 | $37K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 268 | 228 | $27K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 367 | 356 | $20K |
62 more codes
| 84484 | <1% | 2,112 | $18K | |
| 80179 | <1% | 868 | $16K | |
| 82077 | <1% | 871 | $15K | |
| 80143 | <1% | 754 | $13K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 235 | $12K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,620 | $11K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 75 | $11K |
| 76801 | <1% | 72 | $10K | |
| 81001 | <1% | 3,876 | $8K | |
| 84703 | <1% | 1,113 | $8K | |
| 83690 | <1% | 987 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 555 | $5K |
| 86850 | <1% | 209 | $5K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 45 | $4K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 252 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 382 | $4K |
| G0378 | Hospital observation service, per hour | <1% | 23 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 619 | $3K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 46 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,296 | $3K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 75 | $3K |
| 87081 | <1% | 398 | $2K | |
| 59025 | Fetal non-stress test | <1% | 43 | $2K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,663 | $2K |
| 84702 | <1% | 191 | $2K | |
| 83605 | <1% | 256 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 949 | $2K |
| 81003 | <1% | 1,339 | $2K | |
| 85610 | <1% | 707 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 35 | $1K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 54 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 615 | $990.51 |
| 81025 | <1% | 110 | $889.11 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 14 | $786.19 |
| 84112 | <1% | 12 | $780.10 | |
| 86900 | <1% | 249 | $748.33 | |
| 86901 | <1% | 249 | $739.58 | |
| 80320 | <1% | 54 | $629.89 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 633 | $595.88 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,368 | $592.49 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 71 | $558.61 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 120 | $542.32 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 173 | $526.97 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 211 | $503.18 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 17 | $317.81 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 291 | $311.76 |
| 87040 | <1% | 52 | $300.68 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,519 | $194.06 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 59 | $146.92 |
| 80076 | <1% | 27 | $135.48 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 85 | $77.04 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 59 | $51.33 |
| 87186 | <1% | 15 | $46.70 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13 | $43.31 |
| 82947 | <1% | 41 | $35.16 | |
| 85027 | <1% | 15 | $27.52 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 13 | $14.11 |
| 85730 | <1% | 15 | $13.69 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 13 | $0.00 |
| A9270 | Non-covered item or service | 0% | 815 | $0.00 |
| 82962 | 0% | 207 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOYLE, JOHN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Steward ST. Annes Hospital Corporation | Fall River, MA | $82.71M |
| Steward Trumbull Memorial Hospital, INC. | Warren, OH | $16.49M |
| Steward Sharon Regional Health System, INC. | Sharon, PA | $6.76M |
| Steward Rockledge Hospital, INC. | Rockledge, FL | $6.16M |
| Steward Sharon Regional Health System, INC. | Sharon, PA | $5.84M |
| SHC Youngstown Ohio Laboratory Services Company LLC | Poland, OH | $3.41M |
| Steward Melbourne Hospital, INC. | Melbourne, FL | $3.35M |
| Steward Hillside Rehabilitation Hospital, INC. | Warren, OH | $2.74M |
| Steward Sebastian River Medical Center, INC. | Sebastian, FL | $2.16M |
| Steward Northside Medical Center, INC. | Youngstown, OH | $1.58M |
| Steward Rockledge Hospital, INC. | Rockledge, FL | $974K |
| Newberry County EMS | Newberry, SC | $758K |
| Steward Sharon Regional Health System, INC. | Mercer, PA | $181K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.